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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of different techniques and types of laser photocoagulation treatment for PDR. We will compare different
wavelengths; power and pulse duration; pattern, number and location of burns versus standard argon laser single spot treatment as
defined by ETDRS.
B A C K G R O U N D
Description of the condition
Diabetic retinopathy (DR) is a chronic progressive, potentially
sight-threatening disease of the retinal microvasculature associated
with prolonged hyperglycaemia. As the leading cause of blindness
among working-aged adults around the world, DR is a major pub-
lic health problem (Klein 2007). Its incidence is rising dramati-
cally along with the incidence of type 2 diabetes, driven by greater
longevity combined with sedentary lifestyles and increasing lev-
els of obesity (Geiss 2011). Globally, there are approximately 93
million people with DR, including 17 million with proliferative
DR, 21 million with diabetic macular oedema, and 28 million
with vision-threatening diabetic retinopathy (VTDR) (Yau 2012).
A pooled analysis from diabetic population-based studies around
the world found overall prevalence rates of 34.6% for any DR,
6.96% for proliferative DR, 6.81% for diabetic macular oedema
and 10.2% for VTDR. All DR prevalence endpoints increased
with diabetes duration, haemoglobin A(1c), and blood pressure
levels and were higher in people with type 1 compared with type
2 diabetes (Yau 2012).
These data highlight the substantial worldwide public health bur-
den of DR and the importance of tackling modifiable risk factors
to reduce its occurrence. The Diabetes Control and Complica-
tions Trial (DCCT) showed that intensive glycaemic control was
effective in delaying the onset, as well as slowing the progression,
of DR in patients with type 1 diabetes (DCCT Research Group
1993). The UK Prospective Diabetes Study (UKPDS) showed
the risk of complications in type 2 diabetics was independently
and additively correlated with hyperglycaemia and hypertension,
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with risk reductions of 21% per 1% decrease in HbA1c and 11%
per 10 mmHg decrease in systolic blood pressure (Stratton 2006;
UKPDSGroup 1998). There are various classifications of diabetic
retinopathy, but all recognise the two basic mechanisms leading
to loss of vision: retinopathy (risk of developing new vessels) and
maculopathy (risk of damage to the central fovea). For the pur-
poses of this review, we are concerned with vision-threatening di-
abetic retinopathy, defined by the presence of abnormal new ves-
sels. The differences between classifications relate mainly to levels
of retinopathy and to terminology used. Severity is ranked into a
stepwise scale from no retinopathy through various stages of non-
proliferative or pre-proliferative disease to advanced proliferative
disease (ETDRS Research Group 1991).
Proliferative diabetic retinopathy (PDR) is characterised by its lo-
cation and its severity. With regard to location, there may be new
vessels on the disc (NVD) or within 1 disc diameter (DD) of the
margin of the disc; elsewhere in the retina (NVE) and associated
with haemorrhage; or on the iris (NVI). Severity is classified as
early PDR; PDR with high risk characteristics, such as NVD > 1/
4 DD, any NVD or NVE associated vitreous haemorrhage; florid
PDR; and gliotic PDR. ’Involutionary’ PDR refers to new vessels
that have regressed, usually in response to treatment but (rarely)
spontaneously.
Description of the intervention
Laser photocoagulation reduces the oxygen demand of the outer
layers of the retina and helps divert adequate oxygen and nutri-
ents to the inner retinal layers, favourably altering the haemody-
namics (Stefánsson 2001). Laser photocoagulation may also act
by reducing the expression of vasoactive factors such as vascular
endothelial growth factor (VEGF) and protein kinase C (PKC) in
the retina (Ghosh 2005). Indeed, different landmark studies have
supported the efficacy of laser pan-retinal photocoagulation (PRP)
in preventing vision loss. The Diabetic Retinopathy Study (DRS)
demonstrated that laser photocoagulation of the retina reduced se-
vere visual loss (defined as visual acuity of 5/200 or less on two con-
secutive visits at least four months apart) (DRS Research Group
1978), and the Early Treatment Diabetic Retinopathy Study (ET-
DRS) addressed the question of the appropriate time for per-
forming laser photocoagulation, showing that PRP was beneficial
only in cases where proliferative changes were present or immi-
nent (ETDRS Research Group 1985). It also showed that focal or
grid photocoagulation was beneficial in reducing visual loss due
to macular oedema (ETDRS Research Group 1985). Laser PRP
is more beneficial when performed at an advanced stage of the
disease, when proliferative changes have appeared and are threat-
ening vision. This treatment is associated with its own morbidity,
so as the disease progresses to the PDR stage the risk-benefit ratio
is altered in favour of PRP. The visual loss due to PRP is much
less debilitating at this stage compared with the high risk of severe
vision loss in the near future if the retinopathy were to remain
untreated (Feman 2004).
How the intervention might work
Proliferative diabetic retinopathy (PDR) is the angiogenic response
of the retina to extensive capillary closure. New vessels grow at the
interface of perfused and non-perfused retina and are described as
NVD or NVE. Other sites of new vessels include the iris (NVI),
which suggest more advanced and widespread ischaemia. Periph-
eral retinal ischaemia, in the absence of surrogate markers or cap-
illary drop out (blot haemorrhage, venous beading, intraretinal
microvascular anomalies) may not always be readily discernible
clinically, and hence retinal angiography especially wide field
retinal angiography is useful in detecting ischaemic changes.
The aim of laser PRP treatment is to destroy the areas where there
is capillary non-perfusion and retinal ischaemia. If there is an in-
adequate response without full regression of new vessels, then clin-
icians should repeat the treatment. Lasers act by inducing ther-
mal damage after absorption of energy by tissue pigments. The
three main retinal pigments are luteal pigment, haemoglobin and
melanin, and the appropriate laser wavelength will be selectively
absorbed in one of these pigments. The goal of PRP is to target
the retinal pigment epithelium (RPE) with minimal photorecep-
tor damage and RPE cell loss, and barely visible scar formation
within the outer retina.
Following the guidelines published by the DRS and ETDRS, ar-
gon laser photocoagulation has been the gold standard for the
treatment of PDR. Level 1 evidence from the DRS recommended
multisession PRP laser extending into far-peripheral zones in high-
risk eyes (DRS Research Group 1981). Practioners still widely fol-
low this guideline as a frame of reference, generating peak energy
production in the 514 nm wavelength. At the same time, reason-
able modifications may be applied to different clinical scenarios,
and the guidelines do not necessarily represent an absolute start
or endpoint of therapy. In a practical sense, the clinical goal is
to administer enough laser burns to ischaemic retina to induce
regression of active neovascularisation, preventing new lesions or
haemorrhage. This includes 360° treatment in the case of PDR,
with adequate spacing to avoid excessive compromise of periph-
eral vision. There are no standard power settings, since burn ade-
quacy is dependent on variables such as media clarity, fundus pig-
mentation, and method of delivery, but the goal is to achieve an
adequate blanching of the outer neural retina with medium grey
spots. Avoiding intense white spots will reduce the risk of inducing
haemorrhage and foci for retinal breaks or choroidal neovasculari-
sation. Dividing the PRP treatment into two or more sessions can
help minimise the occurrence of adverse effects (Doft 1982).
Different laser strategies can also help reduce ocular side effects,
such as laser burn scarring and visual field loss (Muqit 2010).
Argon-dye laser photocoagulators produce optical radiations in
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the visible spectrum. However the newer “yellow” wavelength
lasers have the highest combined absorption in themelanin-oxyhe-
moglobin layers of the RPE/choriocapillaris complex and thought
to induce less scatter with increased efficiency compared to green
laser photocoagulators (Castillejos-Rios 1992).
MicroPulse is a tissue-sparing laser technology that can limit tissue
thermal elevation to temperatures below the threshold of retinal
tissue damage and induce beneficial intracellular biological effects
without any visible laser-induced damage. Reported MicroPulse
protocols have use both diode laser which produces energy in the
invisible infrared band (810 nm), and the 577 nm (yellow) laser.
Both these laser treatment strategies can be either continuous or
subthreshold (MicroPulse) and targets themelaninwithin theRPE
for photothermal effects, with minimisation of functional and
structural damage to the outer retina since there is no absorption
by photoreceptors and haemoglobin (Pollack 1998). The lack of a
bright flash provides more patient comfort, with minimal retinal
bleaching and rapid recovery from the laser treatment. However,
the resulting retinal laser burn may be more difficult to assess clin-
ically. The MicroPulse laser has been adapted to fire in a rapid
sequence micropulse mode where there are short applications of
laser. A major issue for clinicians is that laser titration may be
difficult in the absence of visible laser uptake, with risks of over-
lapping retreatment burns. Additionally, the subthreshold diode
micropulse (SDM) laser burns are not visualised using fundus
autofluorescence (FAF) or optimal coherence tomography (OCT)
techniques (Luttrull 2006).
Clincians increasingly use the PASCAL (PAttern SCAn Laser)
frequency-doubled neodymium-doped yttrium aluminium garnet
solid-state laser with a wavelength of 532 nm. Power settings for
PASCAL are generally double that of argon for comparable treat-
ments. However, pulse duration is one-fifth that of conventional
argon laser treatment so application of laser burns may be quicker
and less painful (Muraly 2011). There are multispot laser deliv-
ery systems that allow a pulse duration of 10 to 30 ms compared
with the 100 to 200 ms used with conventional laser. Addition-
ally, the procedure can be semiautomated by delivering multiple
laser burns to the retina with a single depression of the foot pedal.
Multispot laser treatment for PDR has been shown to be safe and
effective, preserving central visual acuity as well as peripheral vi-
sual field (Muqit 2010). Shorter duration of laser pulse has been
demonstrated to be more favourable for pain (Al-Hussainy 2008;
Muqit 2010). It is recognised that if laser treatment is applied
using a shorter duration of pulse (e.g. 20 ms), a larger number
of burns are needed to achieve control of PDR, either in a single
session or multiple sessions (Muraly 2011).
Why it is important to do this review
Current NICE guidelines for the management of PDR recom-
mend that an ophthalmologist promptly perform a course of full
argon laser therapy and continue until regression of neovascular-
isation (Ghanchi 2013). However, most of the evidence base re-
lies on the previously described landmark trials, which use older
lasers from the 1980s, and it does not provide enough evidence
to recommend newer laser techniques. There is growing evidence
that treatment with newer laser machines may be equally effective
but safer and less uncomfortable. We think that there should be a
high quality review of alternative laser treatments, including mod-
ern lasers, to reduce harm from photocoagulation. This systematic
review is designed to examine efficacy and safety in people with
PDR treated with alternative types of laser. We will also assess the
evidence base for alternative laser strategies such as a step-wise ap-
proach with an initial light-scattered PRP, with further laser if the
retinopathy does not regress; and ischaemia-targeted laser to the
peripheral retina as seen on fluorescein angiography with the aid
of wide field imaging compared with standard argon laser. This
review will follow on from the preliminary work carried out by
Evans 2014 in a recentCochrane review assessing the effects of laser
photocoagulation for DR compared to no treatment or deferred
treatment. Pan-retinal photocoagulation has been the mainstay of
treatment of PDR for many years, but future Cochrane reviews on
variations in the laser treatment protocol were recommended. A
NIHR-HTA project (12/71/01) addressed a similar question but
in different populations, with earlier disease than in our proposed
review (Royle 2015).
O B J E C T I V E S
To assess the effects of different techniques and types of laser pho-
tocoagulation treatment for PDR.Wewill compare differentwave-
lengths; power and pulse duration; pattern, number and location
of burns versus standard argon laser single spot treatment as de-
fined by ETDRS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will only include randomised controlled trials (RCTs) in this
review.
Types of participants
Wewill include people with type 1 or 2 diabetes mellitus of all ages
and both sexes with PDR as defined in the included studies. We
will include a subgroup of trials where participants have received
previous pharmacological treatments for diabetic eye disease. We
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will not exclude studies that enrolled participants with other asso-
ciated retinal diseases such as retinal vein occlusion as long as the
diabetic subgroup with PDR is clearly identified and the reason
for laser is PDR.
Types of interventions
We will include RCTs that consider the types of peripheral laser
pan-retinal photocoagulation (PRP) for PDRdescribed below, and
we will only include studies with a comparator group of standard
argon laser PRP.
Interventions
We will compare variations of the following parameters to the
standard argon laser single spot treatment (comparator).
Wavelength
Any ophthalmic laser type (wavelength) including but not limited
to:
• diode laser (810 nm);
• pattern scanning laser such as PASCAL (532 nm) or
NAVILAS.
Wewill exclude studies that consider lasers that are not in common
use, such as the xenon arc photocoagulation or ruby laser.
Laser burn application
Any laser burn application method including but not limited to:
• variations in total number of burns required to induce
regression of neovascularisation, including number of laser
sessions required;
• use of multispot pattern laser delivery;
• use of conventional slit lamp (PASCAL) or the fundus
camera-navigated laser (NAVILAS) system.
Location of laser burns
Any laser burn target location including but not limited to is-
chaemia-targeted retinal location.
Laser combined with other treatments
We will include studies in which participants may have also re-
ceived non-laser based therapies for other indications such as dia-
betic macular oedema (DMO), for example, anti-VEGF, intraoc-
ular steroid implants or traditional Chinese medicine; however,
we will treat these as a separate subset.
We will exclude studies that compare laser versus laser plus an-
other non-laser intervention for PDR, as this is covered in another
Cochrane review.
Comparator
The comparator will be standard argon laser single spot treatment
according to ETDRS guidelines. Specifically, the recommenda-
tions in the ETDRS are an initial treatment peripheral scatter laser
treatment consisting of 1200 to 1600 burns of moderate intensity,
200 to 500 µm spot size, with one-half to one-spot diameter spac-
ing. Argon pulse duration is 100 to 200 ms with power titrated to
produce moderate-intensity burns but with full treatment divided
over at least two sessions according to different clinical scenarios
(ETDRS Research Group 1987).
Types of outcome measures
Primary outcomes
The primary outcome will be best-corrected visual acuity (BCVA).
Specifically we will use the proportion of people who lost or gained
at least 15 ETDRS letters (equivalent to 3 ETDRS lines) as mea-
sured on a LogMAR chart at the one and five year time point.
Secondary outcomes
We will look at the following secondary outcomes.
1. Change in mean BCVA (LogMAR) at 12 months and five
years. We will collect data on final value if change is not available.
2. Change in mean best-corrected near visual acuity (NVA) at
12 months and five years. We will collect data on final value if
change is not available.
3. Progression of diabetic retinopathy/maculopathy at 12
months and five years as defined by trial investigators, including
OCT central macular thickness (CMT) where measured.
4. Visual field testing, including mean deviation (MD) and if
failed, the Estermann standard driving test.
5. Patient-reported outcome measure (PROM) for pain
associated with the treatment, and vision-related quality of life
measured using any validated questionnaire, including loss of
driving licence at 12 months and five years.
6. Resource use and costs.
Adverse events
Adverse events at any time: macular oedema, retinal detachment,
vitreous haemorrhage, need for vitrectomy surgery, severe visual
loss (BCVA < 6/60).
Search methods for identification of studies
Electronic searches
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We will search CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (latest issue), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
present), EMBASE (January 1980 to present), the ISRCTN reg-
istry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (
www.clinicaltrials.gov) and theWHOInternational Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We
will not use any date or language restrictions in the electronic
search for trials.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
ISRCTN (Appendix 4), ClinicalTrials.gov (Appendix 5) and the
ICTRP (Appendix 6).
Searching other resources
We will search the reference lists of potentially includable studies
to identify any additional trials. We do not intend to handsearch
conference proceedings for this review.
Data collection and analysis
Selection of studies
Two authors will independently review all the titles and abstracts
identified from the electronic and manual searches against the
inclusion criteria using web-based review management software (
covidence.org). We will obtain full-text copies of all potentially
or definitely relevant articles. We will contact trial investigators
for further information if required. We will resolve discrepancies
between authors as towhether or not studiesmeet inclusion criteria
by discussion. We will document the excluded studies and the
reasons for exclusion.
Data extraction and management
We will extract the following participant and trial characteristics
and report them in a table format (Appendix 7).
• Participant characteristics (age, sex, glycated haemoglobin
(HbA1c), cholesterol, blood pressure, diagnostic criteria used for
PDR, baseline visual acuity, OCT-determined CMT, and areas
of ischaemic retinal tissue according to fluorescein angiography).
• Intervention (laser agent, laser settings, number of spots
delivered, treatment interval and number, retinal target location).
• Methodology (group size, randomisation, blinding).
• Outcomes data as specified above.
Wewill contact trial investigators for key unpublished information
that is missing from reports of included studies. Two review au-
thors will independently extract the data, entering data into web-
based review management software (Covidence 2015), and using
pre-piloted data extraction templates. Covidence will enable us to
compare discrepancies, which we will resolve by discussion. We
will directly import data from Covidence into Review Manager 5
(RevMan 2014).
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
the included trials according to Chapter 8 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will consider the following main criteria.
• Selection bias: random sequence generation, allocation
concealment.
• Performance bias: blinding of participants, researchers and
outcome assessors.
• Attrition bias: loss to follow-up, rates of adherence.
• Reporting bias: selective outcome reporting. We will report
each parameter as being at high, low, or unclear risk of bias,
resolving any discrepancies between the authors by discussion.
We will contact study authors to clarify study details relating to
any unclear risk of bias. If there is no response from the authors,
we will classify the trial based on available information.
See Table 1 for additional information on assessment of risk of
bias.
Measures of treatment effect
We will measure treatment effect according to the data types de-
scribed in Chapter 9 of the Cochrane Handbook for Systematic Re-
views of Interventions (Deeks 2011). These include the following.
Dichotomous data
Variables in this group include the primary outcome and the pro-
portion of participants experiencing an adverse event during fol-
low-up. We will report dichotomous variables as risk ratios (RRs)
with 95% confidence intervals (CIs).
Continuous data
We will report continuous variables including mean change in
visual acuity as mean difference with 95% CI (if normally dis-
tributed) or median and interquartile range (if not normally dis-
tributed).
Counts and rates data
Wewill measure the number of adverse events experienced by each
participant as counts and rates data. If these adverse events occur
commonly, we will analyse them as dichotomous variables. If the
adverse events occur rarely, we will use the Peto odds ratio.
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Qualitative data
We will report the types of adverse event, resource use and quality
of life data qualitatively as a narrative description of qualitative
data.
Unit of analysis issues
The unit of analysis for efficacy of treatment and ocular safety will
be the eye for which authors have reported the data. Trials may
randomise one or both eyes to the intervention or comparator. If
people are randomly allocated to treatment but only one eye per
person is included in the trial, then there will not be a unit of
analysis issue. In these cases, we will document how investigators
selected the eye. If people are randomly allocated to treatment but
both eyes are included and reported, we will analyse as clustered
data and adjust for within-person correlation. We may have to
contact the trial investigators for further information to do this. If
the study is a within-person study, that is, if one eye is randomly
allocated to intervention and the other eye receives the comparator,
thenwewill analyse as paired data.Wemay have to contact the trial
investigators for further information to do this.The unit of analysis
for economic and quality of life measures will be the individual.
Dealing with missing data
We will seek key unpublished information that is missing from
reports of included studies by contacting study authors. If possi-
ble, we will conduct an intention-to-treat (ITT) analysis. We will
use imputed data if computed by the trial investigators using an
appropriate method but will not impute missing data ourselves.
If ITT data are not available, we will do an available case analy-
sis. This assumes that data are missing at random. We will assess
whether this assumption is reasonable by collecting data from each
included trial on the number of participants excluded or lost to
follow-up and reasons for loss to follow-up by treatment group, if
reported.
Assessment of heterogeneity
We will examine the overall characteristics of the studies, in par-
ticular the type of participants and types of interventions, to as-
sess the extent to which the studies are similar enough to make
pooling study results sensible. We will look at the forest plots of
study results to see how consistent the results of the studies are, in
particular looking at the size and direction of effects. We will as-
sess heterogeneity between trial results using the I2 value (Higgins
2011). We will consider I2 values of greater than 50% to represent
substantial inconsistency but will also consider the Chi2 P value.
As this may have low power when there are few studies, we will
consider P values less than 0.1 to indicate statistical significance
of the Chi2 test.
Assessment of reporting biases
If we find 10 studies or more, we will create a funnel plot and
interpret asymmetry as indicating possible publication bias.
Data synthesis
If there is no substantial clinical or statistical heterogeneity be-
tween the trials, we will combine the results in a meta-analysis
using a random-effects model. We will use a fixed-effect model if
there are three trials or fewer. In case of substantial clinical or statis-
tical heterogeneity, we will not combine study results but present
a narrative or tabulated summary. An exception where pooling
of data would still take place is if we detect substantial statistical
heterogeneity but examination of the forest plot indicates the in-
dividual trial results are all consistent in their direction of effect
(i.e. the risk ratios or mean differences largely fall on one side of
the null line).
Subgroup analysis and investigation of heterogeneity
We will consider clinical sources of heterogeneity including the
type of diabetes, stability of glycaemic, lipid and blood pressure
control, baseline visual acuity, baseline central macular thickness,
and previous treatments for PDR.Wewill conduct subgroup anal-
yses to investigate clinical heterogeneity. When parameters are
available, we will stratify data according to baseline visual acuity
worse than 6/24 Snellen equivalent (55 LogMAR letters), baseline
CMT as measured by OCT greater than 400 µm, and type 1 or
2 diabetes. We will only perform these subgroup analyses for the
primary outcome of this review.
Sensitivity analysis
We will conduct sensitivity analyses to determine the impact of
exclusion of studies with lower methodological quality (defined as
being at high risk of bias in one or more domains), unpublished
data and industry-funded studies. We will only perform the sen-
sitivity analyses for the primary review outcomes.
Summary of findings table
A ’Summary of findings’ table will provide key information con-
cerning the certainty of the evidence, the magnitude of effect of
the interventions examined, and the sum of available data on all
specified review primary and secondary outcomes for a given com-
parison. If data are not available in suitable format, we will provide
a narrative summary in the table.
The ’Summary of findings’ table will include the following six key
outcomes.
1. Loss of vision of three lines at one and five years.
2. Progression of diabetic retinopathy at one and five years as
defined by trial investigators, including OCT central macular
thickness (CMT) where measured.
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3. Adverse events at any time: macular oedema, retinal
detachment, vitreous haemorrhage, need for vitrectomy surgery,
severe visual loss (BCVA < 6/60).
4. Visual field loss, including failed Estermann standard
driving test.
5. PROM: significant pain during the laser procedure.
6. PROM: vision-related quality of life measure using any
validated questionnaire at one and five years.
Two review authors will independently use the GRADE approach
to assess the certainty of the evidence in the included studies using
GRADEpro GDT software (GRADEpro 2014). We will resolve
discrepancies by discussion.
We will calculate the assumed risk from the median risk in the
comparator group of the included studies, unless there are com-
pelling reasons to suggest that this is not the best estimate, inwhich
case we will provide a rationale for the source.
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias
Item Low Unclear High
Sequence generation Computer generated list, ran-
dom table, other method of
generating random list
Not reported how list was gen-
erated. Trial may be described
as ’randomised’ but with no fur-
ther details
Alternate allocation, date of
birth, records (review authors
should exclude these RCTs)
Allocation concealment Central centre (web/telephone
access), sealed opaque
envelopes
Not reported how allocation
administered. Trial may be de-
scribed as ’randomised’ butwith
Investigator involved in treat-
ment allocation or treatment al-
location clearly not masked
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Table 1. Risk of bias (Continued)
no further details
Blinding (masking) of partici-
pants and personnel
Clearly stated that participants
and personnel (apart from doc-
tor) not aware of which lens re-
ceived
Described as ’double-masked’
with no information on who
was masked
No information onmasking. As
lenses different we will assume
that in absence of reporting on
this participants and personnel
were not masked
Blinding (masking) of outcome
assessors
Clearly stated that outcome as-
sessors were masked
Described as ’double-masked’
with no information on who
was masked
No information onmasking. As
lenses different we will assume
that in absence of reporting on
this outcome assessors were not
masked
Incomplete outcome data Missing data less than 20% (i.e.
more than 80% follow-up) and
equal follow-up in both groups
and no obvious reason why loss
to follow-up should be related
to outcome
Follow-up not reported ormiss-
ing data > 20% (i.e. follow-up
< 80%) but follow-up equal in
both groups
Follow-up different in each
group and related to outcome
Selective outcome reporting All outcomes in protocol, tri-
als registry entry or both are re-
ported
No access to protocol or trials
registry entry
Outcomes in protocol or tri-
als registry entry selectively re-
ported
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#2 diabet* near/3 retinopath*
#3 proliferat* near/3 retinopath*
#4 diabet* near/3 maculopath*
#5 neovasculari?ation
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Light Coagulation] explode all trees
#8 MeSH descriptor: [Lasers, Gas] this term only
#9 photocoagulat*
#10 photo next coagulat*
#11 (focal or grid or scatter) near/3 laser*
#12 coagulat* or argon or krypton or YAG or diode or micropulse or Pascal or panretinal
#13 #7 or #9 or #10 or #11 or #12
#14 #6 and #13
9Different lasers and techniques for proliferative diabetic retinopathy (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp diabetic retinopathy/
14. (diabet$ adj3 retinopath$).tw.
15. (proliferat$ adj3 retinopath$).tw.
16. (diabet$ adj3 maculopath$).tw.
17. neovasculari?ation.tw.
18. or/13-17
19. exp light coagulation/
20. lasers, gas/
21. photocoagulat$.tw.
22. (photo adj1 coagulat$).tw.
23. ((focal or grid or scatter) adj3 laser$).tw.
24. (coagulat$ or argon or krypton or YAG or diode or micropulse or Pascal or panretinal).tw.
25. or/19-24
26. 18 and 25
27. 12 and 26
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
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21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp diabetic retinopathy/
34. (diabet$ adj3 retinopath$).tw.
35. (proliferat$ adj3 retinopath$).tw.
36. (diabet$ adj3 maculopath$).tw.
37. neovasculari?ation.tw.
38. or/33-37
39. exp laser coagulation/
40. argon laser/
41. photocoagulat$.tw.
42. (photo adj1 coagulat$).tw.
43. ((focal or grid or scatter) adj3 laser$).tw.
44. (coagulat$ or argon or krypton or YAG or diode or micropulse or Pascal or panretinal).tw.
45. or/39-44
46. 38 and 45
47. 32 and 46
Appendix 4. ISRCTN search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR micropulse
OR Pascal OR panretinal)
Appendix 5. ClinicalTrials.gov search strategy
diabetic retinopathy AND (laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR micropulse
OR Pascal OR panretinal)
Appendix 6. ICTRP search strategy
diabetic retinopathy = Condition AND laser OR photocoagulation OR coagulation OR argon OR krypton OR YAG OR diode OR
micropulse OR Pascal OR panretinal = Intervention
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Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design Parallel group RCT (i.e. people randomised
to treatment)
Within-person RCT (i.e. eyes randomised
to treatment)
Cluster RCT (i.e. communities randomised
to treatment)
Cross-over RCT
Other, specify
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
Howweremissing data handled? (e.g. avail-
able case analysis, imputation methods)
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/unit of analysis
One eye included in study, specify how eye
selected
Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture one eye and two
eye
Two eyes included in study, eyes received
different treatments, specify if correct pair-
matched analysis done
Participants
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n = )
Comparator (n = )
See MECIR 65 and 70
Number of people randomised to this
group
Drug (or intervention) name
Dose
Frequency
Route of administration
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(Continued)
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
List outcomes
Adverse events reported (Y/N)
Length of follow-up and intervals at which
outcomes assessed
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Reported subgroup analyses (Y/N)
Were trial investigators contacted?
Sources of funding
Declaration of interest
See MECIR 69
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